24 September 2021 - The MSAC Secretariat has published a list of the applications scheduled to be considered at the next PICO Advisory Sub-Committee in December.

The Sub-Committee will consider 10 items including ciltacabtagene autoleucel for patients with refractory or relapsed multiple myeloma.

Read PICO Advisory Sub-Committee agenda